SK(SH:688155)2020-10-28 16:00Financial Performance - Operating revenue for the first nine months reached CNY 301,659,357.58, a 205.75% increase year-on-year[6] - Net profit attributable to shareholders was CNY 31,070,061.09, a significant recovery from a loss of CNY 21,669,097.88 in the same period last year[6] - Basic and diluted earnings per share improved to CNY 0.53 from a loss of CNY 0.39 per share in the previous year[7] - Total revenue for Q3 2020 reached ¥86,157,495.24, a significant increase compared to ¥5,221,975.10 in Q3 2019[31] - Net profit for Q3 2020 was ¥570,876.38, contrasting with a net loss of ¥18,561,890.12 in Q3 2019[32] - The company's total operating revenue for Q3 2020 was approximately ¥78.12 million, a decrease from ¥269.17 million in Q3 2019[34] - The net profit for Q3 2020 was a loss of ¥4.01 million, compared to a loss of ¥20.71 million in the same period last year[35] Asset and Equity Growth - Total assets increased by 106.21% to CNY 1,361,247,204.19 compared to the end of the previous year[6] - Net assets attributable to shareholders increased by 167.38% to CNY 1,076,952,458.78 compared to the end of the previous year[6] - Current assets totaled ¥1,305,491,894.50, compared to ¥614,424,911.48 at the end of 2019, reflecting an increase of about 112.5%[23] - Shareholders' equity surged to ¥1,087,498,627.19 from ¥413,502,465.66, indicating a growth of around 162.5%[25] - Owner's equity surged to ¥1,073,329,100.00 in Q3 2020, up from ¥403,140,421.65 in Q3 2019, showcasing improved financial health[30] Cash Flow and Financing - The net cash flow from operating activities for the first nine months was CNY 6,664,965.04, a recovery from a negative cash flow of CNY 58,191,475.90 in the same period last year[6] - Cash inflow from financing activities in the first three quarters of 2020 was CNY 666,806,671.70, a substantial increase from CNY 20,000,000.00 in the same period of 2019[38] - The company raised ¥645,286,466.25 from its initial public offering on the Sci-Tech Innovation Board, contributing to a net cash flow from financing activities increase of ¥625,286,466.25[16] - The ending balance of cash and cash equivalents as of the end of the third quarter of 2020 was CNY 187,457,315.17, up from CNY 35,353,985.09 at the end of the same period in 2019[38] Expenses and Costs - Research and development expenses accounted for 13.27% of operating revenue, down 18.20 percentage points from the previous year[7] - The operating costs for the same period were RMB 202,797,815.07, reflecting a 225.50% increase from RMB 62,302,903.96 in 2019, primarily due to increased revenue[15] - Operating costs for Q3 2020 were ¥80,823,943.51, up from ¥24,411,629.96 in Q3 2019, indicating a rise in operational expenses[31] - The company incurred sales expenses of ¥2.42 million in Q3 2020, down from ¥3.58 million in Q3 2019[34] Shareholder Information - The total number of shareholders reached 9,384 by the end of the reporting period[11] - The top two shareholders, Wang Yinglin and Pan Yanqing, each hold 25.62% of the shares[11] Government Support - The company received government subsidies amounting to CNY 6,042,600.28 during the reporting period[8] Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to leverage the growing asset base and revenue growth[31]